Tokyo Tape
Sign in
← OncoTherapy Science

Half-year report · HY

4564.TEDINET S100X054
Period2025-04-01 → 2025-09-30
Filed2025-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 42
MetricValuePeriodScopeSource row
Revenue¥432m2025-04-01 → 2025-09-30Cons.Net sales
Revenue¥225m2024-04-01 → 2024-09-30Cons.Net sales
Operating income−¥476m2025-04-01 → 2025-09-30Cons.Operating income
Operating income−¥531m2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income−¥494m2025-04-01 → 2025-09-30Cons.Ordinary income
Ordinary income−¥815m2024-04-01 → 2025-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥545m2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax−¥554m2025-04-01 → 2025-09-30Cons.Income before income taxes
Profit before tax−¥545m2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)−¥555m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥815m2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥546m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income−¥555m2025-04-01 → 2025-09-30Cons.Profit loss
Net income−¥546m2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥1.9bnat 2025-09-30Cons.Assets
Total assets¥1.2bnat 2025-03-31Cons.Assets
Total assets¥1.5bnat 2024-09-30Cons.Total assets (5-year summary)
Total liabilities¥289mat 2025-09-30Cons.Liabilities
Total liabilities¥426mat 2025-03-31Cons.Liabilities
Net assets / equity¥1.6bnat 2025-09-30Cons.Net assets
Net assets / equity¥729mat 2025-03-31Cons.Net assets
Net assets / equity¥1.0bnat 2024-09-30Cons.Net assets (5-year summary)
Cash and deposits¥1.7bnat 2025-09-30Cons.Cash and deposits
Cash and deposits¥834mat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥1.7bnat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥834mat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥1.1bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥528mat 2024-03-31vCons.Cash and cash equivalents
Operating cash flow−¥525m2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥815m2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥579m2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥61m2025-04-01 → 2025-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥279,0002024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.4bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.1bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-1.892025-04-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-3.122024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-2.182024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio81.4%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio57.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio59.9%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 28
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30−¥185,000
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2025-09-30−¥185,000
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥185m
Cancer Precision Medical Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥430m
Cancer Precision Medical Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥430m
Cancer Precision Medical Businessreportable segmentsegment profit2025-04-01 → 2025-09-30−¥7m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2025-04-01 → 2025-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2025-04-01 → 2025-09-30¥2m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥185,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2025-04-01 → 2025-09-30−¥284m
—segment totalrevenue2025-04-01 → 2025-09-30¥432m
—segment totalrevenue external2025-04-01 → 2025-09-30¥432m
—segment totalrevenue intersegment2025-04-01 → 2025-09-30¥185,000
—segment totalsegment profit2025-04-01 → 2025-09-30−¥291m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥135,000
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥178m
Cancer Precision Medical Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥222m
Cancer Precision Medical Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥222m
Cancer Precision Medical Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥94m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue2024-04-01 → 2024-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2024-04-01 → 2024-09-30¥3m
Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥135,000
Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2024-04-01 → 2024-09-30−¥259m
—segment totalrevenue2024-04-01 → 2024-09-30¥225m
—segment totalrevenue external2024-04-01 → 2024-09-30¥225m
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥135,000
—segment totalsegment profit2024-04-01 → 2024-09-30−¥353m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 400
ItemContextValueUnit
Current assetsPrior1YearInstant1105697000JPY
Current assetsInterimInstant1885776000JPY
Investments and other assetsPrior1YearInstant49505000JPY
Investments and other assetsInterimInstant49505000JPY
Noncurrent assetsPrior1YearInstant49505000JPY
Noncurrent assetsInterimInstant49505000JPY
AssetsPrior1YearInstant1155203000JPY
AssetsInterimInstant1935282000JPY
Accounts payable otherPrior1YearInstant161334000JPY
Accounts payable otherInterimInstant126234000JPY
Contract liabilitiesPrior1YearInstant142054000JPY
Contract liabilitiesInterimInstant346000JPY
Income taxes payablePrior1YearInstant2160000JPY
Income taxes payableInterimInstant78076000JPY
Other clPrior1YearInstant22189000JPY
Other clInterimInstant13966000JPY
Current liabilitiesPrior1YearInstant327738000JPY
Current liabilitiesInterimInstant218623000JPY
Long term accounts payable otherPrior1YearInstant51067000JPY
Long term accounts payable otherInterimInstant23212000JPY
Asset retirement obligations nclPrior1YearInstant47286000JPY
Asset retirement obligations nclInterimInstant47346000JPY
Noncurrent liabilitiesPrior1YearInstant98353000JPY
Noncurrent liabilitiesInterimInstant70559000JPY
LiabilitiesPrior1YearInstant426091000JPY
LiabilitiesInterimInstant289182000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockInterimInstant786335000JPY
Capital surplusPrior1YearInstant27516414000JPY
Capital surplusInterimInstant28252749000JPY
Retained earningsPrior1YearInstant-26908248000JPY
Retained earningsInterimInstant-27463379000JPY
Treasury stockPrior1YearInstant-4000JPY
Treasury stockInterimInstant-4000JPY
Shareholders equityPrior1YearInstant658161000JPY
Shareholders equityInterimInstant1575699000JPY
Subscription rights to sharesPrior1YearInstant70950000JPY
Subscription rights to sharesInterimInstant70400000JPY
Net assetsPrior1YearInstant729111000JPY
Net assetsInterimInstant1646099000JPY
Liabilities and net assetsPrior1YearInstant1155203000JPY
Liabilities and net assetsInterimInstant1935282000JPY
Business revenuePrior1InterimDuration225083000JPY
Business revenueInterimDuration431891000JPY
Cost of salesPrior1InterimDuration289539000JPY
Cost of salesInterimDuration402833000JPY
Research and development expenses sgaPrior1InterimDuration262376000JPY
Research and development expenses sgaInterimDuration286979000JPY
Selling general and administrative expensesPrior1InterimDuration204285000JPY
Selling general and administrative expensesInterimDuration218017000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass